As a potential treatment for hepatocellular carcinoma (HCC) Younis et al. developed LNPs co-encapsulating the chemotherapeutic agent sorafenib (SOR) and siRNA targeting the midkine (MK) gene, which encodes a cytokine that is upregulated and confers SOR resistance in HCC [46]. Here, MDK is linked to hepatocellular carcinoma.